1606 – Request to amend existing MBS Item No 73341 (Fluorescence in situ hybridisation test of tumour tissue from a patient with locally advanced or metastatic non-small cell lung cancer) to add brigatinib

Page last updated: 05 November 2019

Application Detail

Description of Medical Service

Anaplastic lymphoma kinase (ALK) Fluorescence in situ hybridisation (FISH) testing identifies tumours that carry the ALK rearrangement obtained from patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), which is of non-squamous histology or histology not otherwise specified. Subsidy from the Pharmaceutical Benefits Scheme is also being sought for brigatinib for the treatment of patients with the ALK rearrangement.

Description of Medical Condition

ALK-positive locally advanced or metastatic NSCLC, which is of non-squamous histology or histology not otherwise specified.

Reason for Application

Amendment to MBS item

Medical Service Type

Investigative

Previous Application Number/s

Not applicable

Associated Documentation

Application Form

-

Consultation Survey

-

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

-

ESC

-

MSAC

-